94 related articles for article (PubMed ID: 15911705)
1. The issue of statin safety: where do we stand?
Grundy SM
Circulation; 2005 Jun; 111(23):3016-9. PubMed ID: 15911705
[No Abstract] [Full Text] [Related]
2. Genotoxicity evaluation of HMG CoA reductase inhibitor rosuvastatin.
Berber AA; Celik M; Aksoy H
Drug Chem Toxicol; 2014 Jul; 37(3):316-21. PubMed ID: 24245812
[TBL] [Abstract][Full Text] [Related]
3. The statin wars.
McKillop T
Lancet; 2003 Nov; 362(9394):1498. PubMed ID: 14602449
[No Abstract] [Full Text] [Related]
4. Statin-induced myopathy in the rat: relationship between systemic exposure, muscle exposure and myopathy.
Sidaway J; Wang Y; Marsden AM; Orton TC; Westwood FR; Azuma CT; Scott RC
Xenobiotica; 2009 Jan; 39(1):90-8. PubMed ID: 19219751
[TBL] [Abstract][Full Text] [Related]
5. Effects of rosuvastatin and pitavastatin on ischemia-induced myocardial stunning in dogs.
Satoh K; Takaguri A; Itagaki M; Kano S; Ichihara K
J Pharmacol Sci; 2008 Apr; 106(4):593-9. PubMed ID: 18403900
[TBL] [Abstract][Full Text] [Related]
6. Rosuvastatin: winner in the statin wars, patients' health notwithstanding.
Wolfe S
BMJ; 2015 Mar; 350():h1388. PubMed ID: 25787130
[No Abstract] [Full Text] [Related]
7. Preventive effects of bicarbonate on cerivastatin-induced apoptosis.
Kobayashi M; Kaido F; Kagawa T; Itagaki S; Hirano T; Iseki K
Int J Pharm; 2007 Aug; 341(1-2):181-8. PubMed ID: 17553641
[TBL] [Abstract][Full Text] [Related]
8. Effect of medium pH on the cytotoxicity of hydrophilic statins.
Kobayashi M; Kagawa T; Takano R; Itagaki S; Hirano T; Iseki K
J Pharm Pharm Sci; 2007; 10(3):332-9. PubMed ID: 17727796
[TBL] [Abstract][Full Text] [Related]
9. Role of multi-drug resistance-associated protein-1 transporter in statin-induced myopathy.
Dorajoo Rs; Pereira BP; Yu Z; Gopalakrishnakone P; Leong CC; Wee A; Lee E
Life Sci; 2008 Apr; 82(15-16):823-30. PubMed ID: 18509883
[TBL] [Abstract][Full Text] [Related]
10. Rosuvastatin: characterization of induced myopathy in the rat.
Westwood FR; Scott RC; Marsden AM; Bigley A; Randall K
Toxicol Pathol; 2008 Feb; 36(2):345-52. PubMed ID: 18362199
[TBL] [Abstract][Full Text] [Related]
11. FDA approves a statin therapy for some: certain, asymptomatic individuals targeted.
Mitka M
JAMA; 2010 Apr; 303(13):1242-3. PubMed ID: 20371776
[No Abstract] [Full Text] [Related]
12. Photocatalytic degradation of rosuvastatin: analytical studies and toxicity evaluations.
Machado TC; Pizzolato TM; Arenzon A; Segalin J; Lansarin MA
Sci Total Environ; 2015 Jan; 502():571-7. PubMed ID: 25300021
[TBL] [Abstract][Full Text] [Related]
13. Approximate equivalent rosuvastatin doses for temporary statin interchange programs.
Kendrach MG; Kelly-Freeman M
Ann Pharmacother; 2004; 38(7-8):1286-92. PubMed ID: 15187217
[TBL] [Abstract][Full Text] [Related]
14. Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia.
Kei A; Tellis C; Liberopoulos E; Tselepis A; Elisaf M
Cardiovasc Ther; 2014 Aug; 32(4):139-46. PubMed ID: 24618208
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance.
Kennedy SP; Barnas GP; Schmidt MJ; Glisczinski MS; Paniagua AC
J Clin Lipidol; 2011; 5(4):308-15. PubMed ID: 21784377
[TBL] [Abstract][Full Text] [Related]
16. Rosuvastatin and the statin wars--the way to peace.
Meyboom RH; Edwards IR
Lancet; 2004 Dec 4-10; 364(9450):1997-9. PubMed ID: 15582043
[No Abstract] [Full Text] [Related]
17. Combining rosuvastatin with sartans of different peroxisome proliferator-activated receptor-γ activating capacity is not associated with different changes in low-density lipoprotein subfractions and plasma lipoprotein-associated phospholipase A₂.
Rizos CV; Liberopoulos EN; Tellis CC; Florentin M; Elisaf MS; Tselepis AD
Metab Syndr Relat Disord; 2011 Jun; 9(3):217-23. PubMed ID: 21352079
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance.
Backes JM; Venero CV; Gibson CA; Ruisinger JF; Howard PA; Thompson PD; Moriarty PM
Ann Pharmacother; 2008 Mar; 42(3):341-6. PubMed ID: 18285559
[TBL] [Abstract][Full Text] [Related]
19. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
Robinson JG; Nedergaard BS; Rogers WJ; Fialkow J; Neutel JM; Ramstad D; Somaratne R; Legg JC; Nelson P; Scott R; Wasserman SM; Weiss R;
JAMA; 2014 May; 311(18):1870-82. PubMed ID: 24825642
[TBL] [Abstract][Full Text] [Related]
20. Rosuvastatin: renal disorders and rhabdomyolysis.
Prescrire Int; 2007 Apr; 16(88):68-9. PubMed ID: 17458050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
